Compare · BBNX vs MDLN
BBNX vs MDLN
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.60B, about 74.7x BBNX ($610.5M).
- Over the past year, BBNX is down 13.2% and MDLN is down 14.9% - BBNX leads by 1.7 points.
- MDLN has been more active in the news (18 items in the past 4 weeks vs 8 for BBNX).
- MDLN has more recent analyst coverage (25 ratings vs 16 for BBNX).
PerformanceBBNX-53.08%MDLN-14.90%
2025-12-17+0.00%2026-06-22
- Company
- Beta Bionics Inc.
- Medline Inc.
- Price
- $13.70-1.37%
- $34.68-3.43%
- Market cap
- $610.5M
- $45.60B
- 1M return
- +35.33%
- -4.30%
- 1Y return
- -13.24%
- -14.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2025
- News (4w)
- 8
- 18
- Recent ratings
- 16
- 25
Latest BBNX
- Director Jones Christy sold $39,354 worth of shares (2,811 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 27,400 units (SEC Form 4)
- Chief Commercial Officer Hopman Mark sold $3,385 worth of shares (275 units at $12.31) as part of a pre-agreed trading plan, decreasing direct ownership by 0.21% to 130,612 units (SEC Form 4)
- Chief Product Officer Mensinger Mike sold $55,194 worth of shares (4,378 units at $12.61), decreasing direct ownership by 2% to 184,415 units (SEC Form 4) (tax liability)
- Chief Commercial Officer Hopman Mark sold $67,183 worth of shares (5,329 units at $12.61), decreasing direct ownership by 4% to 130,887 units (SEC Form 4) to satisfy withholding tax
- President & CEO Saint Sean sold $212,707 worth of shares (16,872 units at $12.61), decreasing direct ownership by 4% to 420,937 units (SEC Form 4) to cover taxes
- Chief Medical Officer Russell Steven Jon sold $53,227 worth of shares (4,222 units at $12.61), decreasing direct ownership by 2% to 173,849 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Feider Stephen sold $84,165 worth of shares (6,676 units at $12.61), decreasing direct ownership by 4% to 166,053 units (SEC Form 4) to satisfy tax liability
- Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
- Director Palasis Maria was granted 16,965 shares, increasing direct ownership by 136% to 29,397 units (SEC Form 4)
- Director Michel Gerard J was granted 16,965 shares, increasing direct ownership by 103% to 33,509 units (SEC Form 4)
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)